Morgan Stanley Initiates Coverage On Bicycle Therapeutics with Equal-Weight Rating, Announces Price Target of $60

Morgan Stanley analyst Jeffrey Hung initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight rating and announces Price Target of $60.

byBenzinga Newsdesk

February 14, 2022

1 minute read

Morgan Stanley analyst Jeffrey Hung initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight rating and announces Price Target of $60.

News
Tech

Tesla Model S Plaid Event: Live Blog

By Shivdeep Dhaliwal

Today, 11:13 PM

Tesla Inc (NASDAQ: TSLA) is scheduled to begin a delivery event for its Model S Plaid electric vehicle Thursday before midnight, currently expected around 11:00 PM ET.

TSLA

Sierra Metals Late Yesterday Reported Q2 EPS $0.08 Beats $0.01 Estimate, Sales $79.45M Beat $38.23M Estimate

By Benzinga Newsdesk

Today, 11:13 PM

Sierra Metals (AMEX:SMTS) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.01 by 700 percent. This is a 700 percent increase over earnings of $0.01 per share from the same

SMTS

Oppenheimer Maintains Outperform on U.S. Bancorp, Lowers Price Target to $70

By Benzinga Newsdesk

Today, 11:13 PM

Oppenheimer analyst Chris Kotowski maintains U.S. Bancorp (NYSE:USB) with a Outperform and lowers the price target from $71 to $70.

USB

Global
News

Reported Late Monday, Fiserv Looks To Support New Payment Flows With Major Payment Institution License Grant From Monetary Authority Of Singapore Effective January 1, 2023

By Happy Mohamed

Today, 11:13 PM

Company's local operating entity granted license to provide merchant acquisition and domestic and cross-border money transfer services under the Payment Services Act A Fiserv, Inc. (NASDAQ:FISV) operating

FISV

Morgan Stanley Initiates Coverage On Bicycle Therapeutics with Equal-Weight Rating, Announces Price Target of $60

Related Posts

Tesla Model S Plaid Event: Live Blog

Sierra Metals Late Yesterday Reported Q2 EPS $0.08 Beats $0.01 Estimate, Sales $79.45M Beat $38.23M Estimate

Oppenheimer Maintains Outperform on U.S. Bancorp, Lowers Price Target to $70

Reported Late Monday, Fiserv Looks To Support New Payment Flows With Major Payment Institution License Grant From Monetary Authority Of Singapore Effective January 1, 2023